Argenx and Bird Rock Bio Seek To Differentiate Early With Anti-IL6 RA Drug
This article was originally published in Scrip
Executive Summary
Belgian biotech Argenx N.V. is looking to low and infrequent dosing to carve out a place for its novel anti-inflammatory in rheumatoid arthritis.